ATE322906T1 - Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten - Google Patents

Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten

Info

Publication number
ATE322906T1
ATE322906T1 AT01993471T AT01993471T ATE322906T1 AT E322906 T1 ATE322906 T1 AT E322906T1 AT 01993471 T AT01993471 T AT 01993471T AT 01993471 T AT01993471 T AT 01993471T AT E322906 T1 ATE322906 T1 AT E322906T1
Authority
AT
Austria
Prior art keywords
growth factor
treatment
fgf
long
term
Prior art date
Application number
AT01993471T
Other languages
English (en)
Inventor
A Mantovani
B Bottazzi
M Presta
M Rusnati
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE322906T1 publication Critical patent/ATE322906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
AT01993471T 2000-11-08 2001-11-08 Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten ATE322906T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000RM000578A IT1317930B1 (it) 2000-11-08 2000-11-08 Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione

Publications (1)

Publication Number Publication Date
ATE322906T1 true ATE322906T1 (de) 2006-04-15

Family

ID=11454983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01993471T ATE322906T1 (de) 2000-11-08 2001-11-08 Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten

Country Status (21)

Country Link
US (1) US7858577B2 (de)
EP (1) EP1331940B1 (de)
JP (1) JP4167061B2 (de)
KR (1) KR100822357B1 (de)
CN (1) CN1304047C (de)
AT (1) ATE322906T1 (de)
AU (2) AU2002222513B8 (de)
BR (1) BR0115190A (de)
CA (1) CA2428176C (de)
CY (1) CY1106092T1 (de)
CZ (1) CZ299673B6 (de)
DE (1) DE60118769T2 (de)
DK (1) DK1331940T3 (de)
ES (1) ES2261515T3 (de)
HU (1) HU229100B1 (de)
IT (1) IT1317930B1 (de)
MX (1) MXPA03004005A (de)
PL (1) PL205925B1 (de)
PT (1) PT1331940E (de)
SK (1) SK287791B6 (de)
WO (1) WO2002038169A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
WO2005080981A1 (ja) * 2004-02-25 2005-09-01 Perseus Proteomics Inc. 血管障害の程度の判定方法
ITRM20040489A1 (it) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
MX2008009289A (es) * 2006-01-24 2008-10-17 Tecnogen Spa Peptidos de enlace al factor de crecimiento de fibroblasto 2 y usos de los mismos.
EP1832295A1 (de) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Verwendung von PTX3 zur Behandlung viraler Erkrankungen
JP5441685B2 (ja) 2006-05-02 2014-03-12 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ チモシンα１の、単独またはＰＴＸ３またはガンシクロビルとの組合せにおける、サイトメガロウイルス感染の処置のための使用
WO2013191280A1 (ja) * 2012-06-22 2013-12-27 国立大学法人 東京大学 全身性炎症反応症候群の治療又は予防剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571442A4 (de) * 1991-01-14 1995-05-03 Univ New York Cytokin-induzierbares protein tsg-14, seine kodierende dna und ihre verwendung.
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

Also Published As

Publication number Publication date
AU2002222513B8 (en) 2006-11-23
AU2002222513B2 (en) 2006-10-26
PL365292A1 (en) 2004-12-27
KR20030061396A (ko) 2003-07-18
HUP0400541A3 (en) 2006-01-30
JP2004513151A (ja) 2004-04-30
CY1106092T1 (el) 2011-06-08
CZ299673B6 (cs) 2008-10-15
HK1061209A1 (en) 2004-09-10
PT1331940E (pt) 2006-07-31
AU2251302A (en) 2002-05-21
DE60118769D1 (de) 2006-05-24
US20040023879A1 (en) 2004-02-05
ITRM20000578A1 (it) 2002-05-08
CA2428176C (en) 2013-02-05
KR100822357B1 (ko) 2008-04-16
DE60118769T2 (de) 2007-01-04
ES2261515T3 (es) 2006-11-16
US7858577B2 (en) 2010-12-28
SK287791B6 (sk) 2011-10-04
CA2428176A1 (en) 2002-05-16
HU229100B1 (en) 2013-07-29
PL205925B1 (pl) 2010-06-30
BR0115190A (pt) 2004-02-03
WO2002038169A1 (en) 2002-05-16
DK1331940T3 (da) 2006-08-14
EP1331940A1 (de) 2003-08-06
EP1331940B1 (de) 2006-04-12
MXPA03004005A (es) 2004-05-05
CN1304047C (zh) 2007-03-14
HUP0400541A2 (hu) 2004-05-28
JP4167061B2 (ja) 2008-10-15
IT1317930B1 (it) 2003-07-15
CN1473050A (zh) 2004-02-04
SK5622003A3 (en) 2003-10-07
CZ20031179A3 (cs) 2003-11-12

Similar Documents

Publication Publication Date Title
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
SE9103332D0 (sv) Method for the diagnosis of blood coagulation desorders
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
SI1427409T1 (sl) Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BRPI0414215A (pt) tienopirazóis
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
DE60227701D1 (de) Die verwendung von c-kithemmern zur förderung des haarwuchses
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
ATE271881T1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
ATE353642T1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
NO890801D0 (no) Fremgangsmaate for fremstilling av lysyloxydaseinhibitorer.
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
ATE323505T1 (de) Verwendung von rekombinantem lungensurfactant zur frühbehandlung von akuten lungenerkrankungen
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE69809785D1 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
ATE238795T1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE60205911T2 (de) Teilhydrolysierte Fischgelatine enthaltende Zubereitungen und deren Verwendung
ATE42201T1 (de) Verwendung von phytosterolglycosiden zur herstellung von arzneimitteln zur behandlung von erhoehtem 5(6)alpha-epoxycholesterolgehalt.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1331940

Country of ref document: EP